The announcement greeted with a trade of just over 430 shares worth a total of $3.00 which has driven the market value of the ATH down by 12.5%. The announcement was more to do with a new diagnostic approach to diagnose MSA rather than any efficacy results. We just need to be patient and wait till early 2025 when hopefully the results of the phase 2 trial become available. Lets hope there are no further hold ups with patient enrolments and that ATH434 actually shows significant positive efficacy results with the share price back over the $1.00 mark like the good old days.
Ann: Alterity Presents New Data on Multiple System Atrophy, page-2
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $9.051K | 1.899M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 51 | 61886501 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 29700836 | 14 |
View Market Depth
| Last trade - 10.23am 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
0.5¢ |
Change
0.000 ( 10.0 %) |
||||
| Open | High | Low | Volume | ||
| 0.5¢ | 0.5¢ | 0.5¢ | 175000 | ||
| Last updated 14.19pm 04/06/2024 ? | |||||
| ATH (ASX) Chart |